Home > Haematology > EHA 2020 > Lymphoid > PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Presented By
Dr Peter Borchmann, University Hospital of Cologne, Germany
Conference
EHA 2020
Trial
Phase 3, HD17
Data from the HD17 trial indicate that PET-guided omission of radiotherapy for patients with newly diagnosed early-stage unfavourable Hodgkin lymphoma (HL) should be the new standard of care. Dr Peter Borchmann (University Hospital of Cologne, Germany) presented the HD17 study, on behalf of the German Hodgkin Study Group (GHSG) [1]. The standard of care for early-stage HL with risk factors indicating an unfavourable prognosis (“early-stage unfavourable HL”) consists of 4 cycles of chemotherapy [2x BEACOPPescalated (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) and 2x ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)] followed by 30Gy radiotherapy. However, late sequalae such as cardiovascul...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on